Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,019 | 331 | 97.4% |
| Education | $162.54 | 3 | 2.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $1,167 | 72 | $0 (2024) |
| ABBVIE INC. | $935.03 | 55 | $0 (2024) |
| Lilly USA, LLC | $679.35 | 34 | $0 (2024) |
| Astellas Pharma US Inc | $545.03 | 21 | $0 (2024) |
| Merck Sharp & Dohme LLC | $263.78 | 13 | $0 (2024) |
| Amarin Pharma Inc. | $230.94 | 13 | $0 (2022) |
| Abbott Laboratories | $215.48 | 10 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $194.59 | 10 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $187.43 | 12 | $0 (2024) |
| PFIZER INC. | $182.94 | 11 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,129 | 57 | ABBVIE INC. ($290.24) |
| 2023 | $1,319 | 65 | Astellas Pharma US Inc ($367.35) |
| 2022 | $1,257 | 71 | ABBVIE INC. ($313.93) |
| 2021 | $655.42 | 42 | AbbVie Inc. ($252.61) |
| 2020 | $732.17 | 42 | Novo Nordisk Inc ($179.39) |
| 2019 | $216.57 | 13 | Novo Nordisk Inc ($38.19) |
| 2018 | $211.27 | 14 | PFIZER INC. ($40.27) |
| 2017 | $661.60 | 30 | Novo Nordisk Inc ($219.21) |
All Payment Transactions
334 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.18 | General |
| Category: NEUROSCIENCE | ||||||
| 12/10/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $22.66 | General |
| Category: Diabetes | ||||||
| 12/06/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $4.54 | General |
| Category: NEUROSCIENCE | ||||||
| 11/21/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $17.29 | General |
| Category: Diabetes | ||||||
| 11/12/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $34.40 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $19.31 | General |
| Category: Inflammation | ||||||
| 11/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.06 | General |
| Category: NEUROSCIENCE | ||||||
| 10/30/2024 | ABBVIE INC. | UBRELVY (Drug), SYNTHROID | Food and Beverage | In-kind items and services | $24.04 | General |
| Category: NEUROSCIENCE | ||||||
| 10/30/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: Respiratory | ||||||
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.60 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/11/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $19.44 | General |
| Category: Gastroenterology | ||||||
| 10/10/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $18.48 | General |
| Category: Diabetes | ||||||
| 10/08/2024 | Merck Sharp & Dohme LLC | GARDASIL (Biological), CAPVAXIVE, GARDASIL 9 | Food and Beverage | In-kind items and services | $32.18 | General |
| Category: VACCINE | ||||||
| 09/26/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $19.13 | General |
| Category: NEUROSCIENCE | ||||||
| 09/05/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $23.70 | General |
| Category: Biological | ||||||
| 08/27/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $20.60 | General |
| Category: NEUROSCIENCE | ||||||
| 08/23/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $2.65 | General |
| Category: NEUROSCIENCE | ||||||
| 08/19/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $6.10 | General |
| Category: Biological | ||||||
| 08/15/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.46 | General |
| Category: NEUROSCIENCE | ||||||
| 08/13/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $5.19 | General |
| Category: Biological | ||||||
| 08/08/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $20.39 | General |
| Category: NEUROSCIENCE | ||||||
| 08/07/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: Diabetes | ||||||
| 07/30/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $26.96 | General |
| Category: NEUROSCIENCE | ||||||
| 07/25/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $28.00 | General |
| Category: Biological | ||||||
| 07/11/2024 | Amphastar Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $17.74 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 2,365 | 2,978 | $551,149 | $159,779 |
| 2022 | 25 | 2,646 | 3,425 | $683,853 | $229,432 |
| 2021 | 24 | 1,750 | 2,186 | $399,116 | $132,141 |
| 2020 | 31 | 2,127 | 2,877 | $449,011 | $137,644 |
All Medicare Procedures & Services
101 procedure records from CMS Medicare Utilization — Page 3 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 50 | 57 | $21,322 | $6,645 | 31.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 43 | 43 | $19,367 | $5,498 | 28.4% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2021 | 25 | 25 | $10,516 | $4,464 | 42.5% |
| 90670 | Pneumococcal vaccine for injection into muscle | Office | 2021 | 18 | 18 | $7,606 | $4,322 | 56.8% |
| 99495 | Transitional care management services, moderately complexity, requiring face-to-face visits within 14 days of discharge | Office | 2021 | 18 | 19 | $7,832 | $3,120 | 39.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 129 | 130 | $9,454 | $2,289 | 24.2% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time per calendar month | Office | 2021 | 32 | 98 | $9,053 | $2,197 | 24.3% |
| G0444 | Annual depression screening, 15 minutes | Office | 2021 | 106 | 106 | $4,670 | $2,152 | 46.1% |
| 99497 | Advance care planning by the physician or other qualified health care professional, first 30 minutes | Office | 2021 | 21 | 21 | $4,941 | $1,643 | 33.3% |
| G0442 | Annual alcohol misuse screening, 15 minutes | Office | 2021 | 75 | 75 | $2,949 | $1,523 | 51.6% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 129 | 136 | $8,797 | $1,418 | 16.1% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 20 | 20 | $6,008 | $1,345 | 22.4% |
| 77080 | Bone density measurement of the core or central skeleton (e.g., hips, pelvis, spine) | Office | 2021 | 20 | 20 | $2,700 | $842.60 | 31.2% |
| 90756 | Vaccine for influenza derived from cell cultures for injection into muscle, quadrivalent, antibiotic free, 0.5ml dosage | Office | 2021 | 18 | 19 | $1,249 | $520.99 | 41.7% |
| G0009 | Administration of pneumococcal vaccine | Office | 2021 | 29 | 29 | $2,081 | $511.29 | 24.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 142 | 168 | $1,344 | $502.91 | 37.4% |
| 99439 | Chronic care management services, each additional 20 minutes of clinical staff time per calendar month | Office | 2021 | 13 | 14 | $1,414 | $354.86 | 25.1% |
| G0403 | Electrocardiogram, routine ecg with 12 leads; performed as a screening for the initial preventive physical examination with interpretation and report | Office | 2021 | 27 | 27 | $1,252 | $246.05 | 19.6% |
| 81002 | Urinalysis, manual test | Office | 2021 | 26 | 29 | $261.00 | $100.92 | 38.7% |
| 96127 | Brief emotional or behavioral assessment | Office | 2021 | 16 | 20 | $372.00 | $56.44 | 15.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 229 | 229 | $57,529 | $29,063 | 50.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 289 | 598 | $138,437 | $21,171 | 15.3% |
| 99497 | Advance care planning by the physician or other qualified health care professional | Office | 2020 | 120 | 143 | $24,152 | $10,088 | 41.8% |
| 99490 | Chronic care management services at least 20 minutes per calendar month | Office | 2020 | 71 | 291 | $26,673 | $9,367 | 35.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 177 | 244 | $38,074 | $6,518 | 17.1% |
About Dr. Debra Curtis, M.D
Dr. Debra Curtis, M.D is a Internal Medicine healthcare provider based in Catonsville, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1083729065.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Debra Curtis, M.D has received a total of $6,181 in payments from pharmaceutical and medical device companies, with $1,129 received in 2024. These payments were reported across 334 transactions from 40 companies. The most common payment nature is "Food and Beverage" ($6,019).
As a Medicare-enrolled provider, Curtis has provided services to 8,888 Medicare beneficiaries, totaling 11,466 services with total Medicare billing of $658,996. Data is available for 4 years (2020–2023), covering 101 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Location Catonsville, MD
- Active Since 08/20/2006
- Last Updated 01/22/2018
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1083729065
Products in Payments
- VRAYLAR (Drug) $438.27
- Ozempic (Drug) $426.38
- Rybelsus (Drug) $393.11
- Veozah (Drug) $375.82
- JARDIANCE (Drug) $307.62
- UBRELVY (Drug) $252.17
- TRULICITY (Drug) $241.73
- Vascepa (Drug) $230.94
- MOUNJARO (Drug) $202.14
- NURTEC ODT (Drug) $200.32
- QULIPTA (Drug) $186.50
- Cologuard Collection Kit (Device) $170.93
- XIFAXAN (Drug) $149.41
- FARXIGA (Drug) $133.63
- QUVIVIQ (Drug) $123.74
- NIOX VERO DEVICE (Device) $110.00
- Tresiba (Drug) $110.00
- Victoza (Drug) $106.03
- EMGALITY (Drug) $101.75
- ZOSTAVAX (Biological) $88.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Catonsville
Charles Moore, M.d, M.D
Internal Medicine — Payments: $10,315
Dr. Robert Ammlung, M.d, M.D
Internal Medicine — Payments: $8,640
Dr. Scott Poulton, M.d, M.D
Internal Medicine — Payments: $8,200
Dr. Benjamin Lee, M.d, M.D
Internal Medicine — Payments: $6,688
Douglas Pinto, Md, MD
Internal Medicine — Payments: $5,781
Dr. Gregory Levickas, Md, MD
Internal Medicine — Payments: $4,697